prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |review
In closing this lecture as well as this series, it is important to note that despite the variety of educational and career opportunities in exposure or risk assessment, the growth rate of toxicologic epidemiology is likely already at its peak. This prediction is based on the observation that many assessment methodologies and developments have been made in recent years, only to the point that they have become a burden rather than tools in regulating health risk.

For example, while analytical methods now allow the detection of chemicals easily down to parts per billion or even per trillion, probabilistic analysis and physiologically-based pharmacokinetic modeling for exposure assessment nowadays are well received at least in concept (see Lecture 3). Although these analytical and modeling techniques theoretically yield more accurate and precise dose estimations, they rely on a much larger, ever lacking database. Their implementations also require both the proper training of the regulatory scientists and, worse yet, the adequate support of the regulatory administrators who may not even have a course in statistics, probability, or pharmacokinetics.

Through regulations and laws, politics has its way that regulatory agencies always bear a huge financial burden of performing risk assessments. For example, for a nominal registration fee from a pesticide registrant, a regulatory agency could spend thousands of person-hours to reach what might still not be a final regulatory decision. True that there is tax levied on pesticides sold in the market, this tax revenue does not get spent directly on the risk assessment for any pesticide, whose (ongoing) registration could even be denied.

Go to Comment Form